Author Archives: Tricia Schneider

PARITY Enrolment Hits 80%!

The PARITY team is thrilled to announce that the trial has reached another major milestone!  On October 26th, the 480th participant was enrolled in the study by Dr. Robert Turcotte, Dr. Krista Goulding and their research team at the McGill University Health Centre in Montreal, QC, Canada.  This is an impressive achievement as this number represents 80% of the total sample size now having been recruited!  The PARITY team expects the next year of recruitment to be the last for the trial.  Thank to everyone who continues to screen and enroll patients!

Singapore General Hospital Enrolls 1st Participant!

Please join us in extending a warm congratulations to Dr. Mann Hong Tan and Dr. Suraya Zainul Abidin at Singapore General Hospital for enrolling their first PARITY participant on October 18, 2018!   Thank you to all those who continue to screen patients for inclusion into the trial.  Without you the success of the trial would not be possible.

PARITY Visits Singapore!

The PARITY Methods Centre team visited the Singapore General Hospital in Singapore on September 25 with the goal of completing the start-up phase and training the site personnel on the study’s operating procedures.  While in Singapore, the PARITY team also attended their monthly orthopaedic journal club meeting.  There are now 54 PARITY sites across Canada, the United States, Australia, Argentina, South Africa, Brazil, Spain, the Netherlands, India, Egypt, Austria and Singapore!

All India Institute of Medical Sciences Recruits 50th PARITY Participant!

Please join us in extending a warm congratulations to Dr. Shah Alam Khan, Dr. Venkatesan Kumar and their research team at the All India Institute of Medical Sciences (New Delhi, India) for enrolling their 50th PARITY participant on September 13, 2018!  They are the first PARITY site to reach such an incredible milestone!

Thank you to all those who continue to screen patients for inclusion into the trial.  Without you the success of the trial would not be possible.

First Austrian Site Open to Enrolment!

We would like to extend a warm welcome to Dr. Marko Bergovec and his research team at the Medical University Graz, which is the latest site to attain enrolment-ready status and is the first Austrian site to participate in the trial.  There are currently 4 European sites actively screening and enrolling patients into the PARITY trial across 3 countries (Spain, the Netherlands and Austria).

PARITY Hits 450 Participants!

The PARITY team is thrilled to announce that the trial has reached another major milestone!  On August 14th, the 450th participant was enrolled in the study by Dr. Robert Turcotte, Dr. Krista Goulding and their research team at the McGill University Health Centre in Montreal, QC, Canada.  This is an impressive achievement as this number represents 75% of the total sample size now having been recruited!  The PARITY team expects the next year of recruitment to be the last for the trial.  Thank to everyone who continues to screen and enroll patients!

Albany Medical Center Enrolls 1st Participant!

Congratulations to Dr. Matt DiCaprio and Brad Palmer at Albany Medical Center (Albany, NY) for enrolling their first PARITY participant today (7 March 2017)!  There are currently 40 sites actively screening and enrolling patients into the PARITY trial across Canada, the United States, Argentina, Brazil, South Africa, Spain, the Netherlands, and India.

Thank you to all those who continue to screen patients for inclusion into the trial.  Without you the success of the trial would not be possible.

UF Health Shands Hospital Enrolls 1st Participant!

Please join us in extending a warm congratulations to Dr. André Spiguel and Alana Jackson at UF Health Shands Hospital (Gainesville, FL) for enrolling their first PARITY participant on 26 January 2017!  There are currently 38 sites actively screening and enrolling patients into the PARITY trial across Canada, the United States, Argentina, Brazil, South Africa, Spain, and the Netherlands.

Thank you to all those who continue to screen patients for inclusion into the trial.  Without you the success of the trial would not be possible.